Indefinite Delivery Contract HHSD200201357341I

The federal contract IDV award to Research Triangle Institute (RTI International) was issued by the U.S. Agency for International Development (USAID) to support activities aimed at expanding and strengthening HIV/AIDS prevention, care, support, treatment, and policy/system strengthening services in the Asia Pacific region. The $650,000,000 multiple-award Indefinite Delivery Contract (IDC), titled "PRH/PEC - NEW MULTIPLE COMPETITIVE IQCS (PDI)," has an ultimate completion date of...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. Valued at up to $107 million over seven years, the contracts authorize task orders across seven areas including in vitro testing, synthesis of therapeutic agents, small animal models, formulation development,...

The Agency for Healthcare Research and Quality (AHRQ), a civilian federal agency, awarded a multiple award indefinite delivery contract (IDC) titled "Accelerating Change and Transformation in Organizations and Networks IV (ACTION IV)" to Research Triangle Institute (RTI) International, a nonprofit research institute. The $5 million ceiling IDC has a period of performance through May 26, 2025. Under this IDC, AHRQ has issued two task orders to RTI. The first, a $2,285,400...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded Sri International a multiple award indefinite delivery contract to provide resources advancing pediatrics and HIV prevention science. Valued at up to $98.8 million over seven years, the contract aims to support preclinical gap filling, animal model studies, bioanalytical services, product manufacturing, and scientific/quality assistance. Sri International has also received a $45,041 delivery order...

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, has awarded a $107,274,471 Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Southern Research Institute, a non-profit research organization, to provide preclinical development support for candidate products and drug development activities related to HIV therapeutics. The contract does not have a set-aside designation and has a period of...

The Centers for Disease Control and Prevention (CDC) awarded a series of firm-fixed-price delivery order contracts under an Indefinite Delivery Contract (IDC) to the non-profit Research Triangle Institute (RTI) International for the "Economic Evaluation of HIV Prevention Interventions." The IDC ceiling value is $3,200,000, with individual delivery orders ranging from $127,657 to $824,940. RTI, a research organization with expertise across public health, economics, and data analysis,...

The National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. The scope of work encompasses seven task areas: in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. The total potential value of the IDV is $107,274,471 over seven years ending October 2027. Task orders have been issued under several areas. Lovelace Biomedical Research Institute received a $18,397 order to develop...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Services will be conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for...

The National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial discovery to clinical trials. Services are conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation development, preclinical pharmacology and...